F77 antigen is a promising target for adoptive T cell therapy of prostate cancer

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has shown success in blood cancers but faces challenges in solid tumors due to limited target antigens.
• Prostate cancer, a significant solid tumor, requires novel therapeutic targets for effective immunotherapy.
• The F77 carbohydrate antigen is present on both androgen-dependent and independent prostate cancer cells, indicating its potential as a universal target.

Purpose of the Study:

• To generate and evaluate a novel second-generation CAR T-cell therapy targeting the F77 carbohydrate antigen on prostate cancer cells.
• To assess the efficacy of F77-specific CAR T cells in vitro and in vivo.

Main Methods:

• Generation of second-generation CARs incorporating CD28 and CD137 (4-1BB) costimulatory domains, utilizing a single-chain variable fragment (scFv) from an F77-specific antibody.
• Transduction of T cells with lentiviral vectors encoding the F77-specific CAR.
• In vitro assessment of cytokine production and tumor cell killing by F77-specific CAR T cells.
• In vivo evaluation of F77-specific CAR T-cell efficacy in a human prostate cancer xenograft model (PC3 cells).

Main Results:

• F77-specific CAR T cells demonstrated cytokine production and tumor cell lysis in an F77 expression-dependent manner.
• Complete eradication of prostate tumors was observed in a human xenograft model using PC3 cells treated with F77-specific CAR T cells.
• The study validates the F77 antigen as a viable target for CAR T-cell immunotherapy.

Conclusions:

• The F77 carbohydrate antigen is a promising immunotherapeutic target for prostate cancer.
• F77-specific CAR T-cell therapy offers a potential new treatment strategy for prostate cancer and other malignancies expressing this antigen.
• Further development of F77-targeted immunotherapies is warranted.